| Website | nucleabio.com |
| Blog | nucleabiomarkers.... |
| @nucleabio | |
| Category | BioTech |
| Phone | 413-749-4705 |
| info@nucleabio.com | |
| Employees | |
| Founded | 2005 |
| TOTAL | $17.3M |
| FUNDING TOTAL | $17.3M |
| Series B, 8/11 | $3M |
| Series B, 10/11 | $3.4M |
| Series B, 2/12 | $3.4M |
| Venture Round, 4/12 | $1.9M |
| Venture Round, 5/12 | $555k |
| Series C, 8/12 | $5M |
Nuclea Biotechnologies, LLC is headquartered in Pittsfield, Massachusetts with additional operations in Worcester, Massachusetts. Nuclea has three lines of business, each of which is operated by a separate wholly-owned subsidiary: Nuclea Diagnostic Laboratories (“NDLâ€) which has developed and is commercializing eleven unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer; Nuclea Biomarkers (“NBMâ€) which performs research leading to novel molecular oncology therapeutics and diagnostics for the pharmaceutical and biotechnology industries and performs services by analyzing and testing the efficacy and validating other indications of existing therapeutics utilizing a highly characterized and consented patient database; and Nuclea Biotherapeutics (“NBTâ€) which has developed several therapeutics now in animal trials.
